Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive: early-phase trial registry

4 of 11 indexed Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

11 US clinical trials · 4 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive: 11 US clinical trials tracked, 4 recruiting.

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.

Enrollment posture brief

Registry condition blast-phase-chronic-myelogenous-leukemia-bcr-abl1-positive

OPEN 4 | RECR 36% | LATE 0 | EARLY 11 | RANK #1577 | SPON 11

Volume-matched condition peers

Nearest open-share peer: Carpal Tunnel Syndrome (36% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Blast Phase Chronic Myel (th…36%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive lists 4 open slots (36% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive is recruiting below its size-band peers.

    4 of 11 indexed trials (36.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive research.

    M.D. Anderson Cancer Center accounts for 11 of 11 trials (100%). 1 distinct sponsors appear on at least one study for this condition label.

  3. Most Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials plan to enrol fewer than 100 people.

    Median target enrolment is 72 among the 11 trials that report a genuine target (sentinel values excluded). 8 of those (72.7%) plan for fewer than 100 participants.

  4. Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive research is mostly interventional.

    11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 28

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 2 508 participants

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

NCT02115295
RECRUITING Phase 2 100 participants

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

NCT03589729
RECRUITING Phase 2 90 participants

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

NCT03263572
RECRUITING Phase 1 58 participants

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

M.D. Anderson Cancer Center

NCT03630991
ACTIVE NOT RECRUITING Phase 2 88 participants

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

NCT01424982
ACTIVE NOT RECRUITING Phase 1 72 participants

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

M.D. Anderson Cancer Center

NCT02530034
ACTIVE NOT RECRUITING Phase 2 22 participants

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

NCT03147612
ACTIVE NOT RECRUITING Phase 2 20 participants

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

NCT04188405
COMPLETED Phase 2 107 participants

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

M.D. Anderson Cancer Center

NCT00390793
COMPLETED Phase 1 54 participants

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

NCT01904136
COMPLETED Phase 2 21 participants

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

M.D. Anderson Cancer Center

NCT01428635

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 8

Top Sponsors

M.D. Anderson Cancer Center 11 trials

Named interventions

Most-linked intervention names on Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cytarabine Drug
6 trials
Cyclophosphamide Drug
4 trials
Laboratory Biomarker Analysis Other
3 trials
Ponatinib Drug
2 trials
Methotrexate Drug
2 trials
Blinatumomab Biological
2 trials
Idarubicin Drug
2 trials
Dexamethasone Drug
2 trials

US sites by state

Facility locations filed on Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials. A trial with sites in several states counts in each.

Texas 11 trials
Utah 1 trials
New York 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive page

11 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • M.D. Anderson Cancer Center sponsors the most Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive condition card totals 11 registered trials; most-linked intervention Cytarabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.